Search

Displaying results 3591 - 3600 of 10000 in total
  1. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  2. Drug

    Lamivudine

    go.drugbank.com/drugs/DB00709
    ApprovedInvestigational

    A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring.

    Mixtures: N/A, N/AProducts: LAVEROS 10 MG/ML ORAL ÇÖZELTİ, 240 ML
  3. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

  4. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor Antagonists
  5. Drug

    Capadenoson

    go.drugbank.com/drugs/DB16118
    Investigational

    Capadenoson is under investigation in clinical trial NCT00518921 (Capadenoson in Angina Pectoris).

    Categories: Adenosine A receptor agonists, Adenosine A1 Receptor Agonists
  6. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  7. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    AG-702 is a recombinant human heat shock protein also known as stress protein. … It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation.

  8. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in

  9. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. … Structurally, Alglucosidase alfa is a glycoprotein with a calculated mass of 98,008 daltons for the 883 residue mature polypeptide chain, and a total mass of approximately 109,000 daltons, including carbohydrates

  10. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors